Lincoln Pharmaceuticals has informed that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendment thereto (‘Regulations’) and Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the Company, the Trading Window for dealing in the securities of the Company shall remain closed from October 01, 2024 till 48 hours after the declaration of the Financial Results of the Company, for the quarter ended September 30, 2024. The date of meeting of the Board of Directors, to approve the Financial Results of the Company for the quarter ended September, 2024, will be informed in due course. Accordingly, all Directors, Senior Management Personnel, Promoter and Promoter Group of the Company and its subsidiaries including their Immediate Relatives and other Connected Persons are advised not to trade in securities of the Company during the aforesaid period of closure of trading window.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: